Levels of adherence to contemporary antiretroviral regimens and the likelihood of viral suppression: a cohort study in a Brazilian metropolis

埃法维伦兹 病毒载量 杜鲁特格拉维尔 拉米夫定 养生 内科学 医学 逻辑回归 队列 抗逆转录病毒疗法 人类免疫缺陷病毒(HIV) 病毒学 病毒 慢性肝炎
作者
Vanessa Aracele Rodrigues,Maria das Graças Braga Ceccato,Juliana de Oliveira Costa,Celline Cardoso Almeida-Brasil,Micheline Rosa Silveira,Edna Afonso Reis
出处
期刊:Aids Care-psychological and Socio-medical Aspects of Aids/hiv [Informa]
卷期号:35 (7): 976-981 被引量:2
标识
DOI:10.1080/09540121.2022.2072802
摘要

Levels of adherence to antiretroviral therapy (ART) can affect the likelihood of viral suppression differentially among ART regimens. In this prospective cohort conducted in Belo Horizonte, Brazil, we included 354 individuals who initiated ART containing tenofovir disoproxil fumarate/lamivudine/efavirenz in fixed-dose combination (TDF/3TC/EFV) or tenofovir disoproxil fumarate/lamivudine associated with dolutegravir (TDF/3TC + DTG). Viral suppression (viral load <50 copies/mL) was evaluated within six months of follow-up at different adherence levels and by therapeutic regimen. Adherence was measured by the Proportion of Days Covered (PDC) and classified into low (≤84%), intermediate (85-89%) or high (≥90%). The association between viral suppression, adherence levels, and other explanatory variables was analyzed using chi-square and multivariable logistic regression. Viral suppression was achieved by 76.0% of individuals and was more frequent among those who achieved higher levels of adherence (high adherence: 79.3%, intermediate: 71.4% and low: 45.2%), those on TDF/3TC + DTG, and those who had viral load ≤100,000 copies/mL at the onset of treatment (p < 0.05). Moreover, individuals on TDF/3TC + DTG had an approximately 90% probability of achieving viral suppression at intermediate adherence levels. These results add new insights on the possibility of lower adherence levels for contemporary antiretroviral regimens currently used as first-line therapy worldwide.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zzzdx完成签到 ,获得积分10
刚刚
阳光绿柏完成签到,获得积分10
刚刚
酷波er应助Bminor采纳,获得10
刚刚
YouY0123完成签到 ,获得积分10
刚刚
haokun完成签到,获得积分10
1秒前
下隔热不发布了新的文献求助10
1秒前
1秒前
whatever应助陈77采纳,获得20
1秒前
1秒前
1秒前
xusansui321完成签到,获得积分10
2秒前
2秒前
从笙完成签到,获得积分10
2秒前
梅西完成签到 ,获得积分10
2秒前
迷路的问玉关注了科研通微信公众号
2秒前
秋澄明发布了新的文献求助10
3秒前
乐乐应助雨碎寒江采纳,获得30
3秒前
jkdzp发布了新的文献求助10
3秒前
Jasper应助氢氧化钠Li采纳,获得10
3秒前
大模型应助追寻的梦岚采纳,获得30
3秒前
漂亮送终发布了新的文献求助10
3秒前
科研通AI2S应助该饮茶了采纳,获得10
3秒前
4秒前
超神奇完成签到,获得积分10
4秒前
baige666发布了新的文献求助10
5秒前
大个应助聪明的冰淇淋采纳,获得10
5秒前
朴素从安发布了新的文献求助10
5秒前
天天快乐应助Assure采纳,获得10
5秒前
天天快乐应助高兴不尤采纳,获得10
5秒前
youyuguang发布了新的文献求助10
6秒前
稗子完成签到,获得积分10
6秒前
沉默的洪纲关注了科研通微信公众号
6秒前
汪金完成签到,获得积分10
6秒前
打打应助快乐的语兰采纳,获得10
6秒前
毛毛应助吴龙采纳,获得10
6秒前
6秒前
Dan完成签到,获得积分10
7秒前
李爱国应助邵123456789采纳,获得10
7秒前
7秒前
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Handbook of pharmaceutical excipients, Ninth edition 5000
Aerospace Standards Index - 2026 ASIN2026 3000
Signals, Systems, and Signal Processing 610
Discrete-Time Signals and Systems 610
Principles of town planning : translating concepts to applications 500
Modified letrozole versus GnRH antagonist protocols in ovarian aging women for IVF: An Open-Label, Multicenter, Randomized Controlled Trial 360
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 纳米技术 有机化学 物理 生物化学 化学工程 计算机科学 复合材料 内科学 催化作用 光电子学 物理化学 电极 冶金 遗传学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 6062247
求助须知:如何正确求助?哪些是违规求助? 7894532
关于积分的说明 16309928
捐赠科研通 5205793
什么是DOI,文献DOI怎么找? 2784995
邀请新用户注册赠送积分活动 1767570
关于科研通互助平台的介绍 1647416